Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$23.14 - $49.68 $11.6 Million - $24.9 Million
-500,615 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$27.77 - $64.4 $2,777 - $6,440
-100 Reduced 0.02%
500,615 $22 Million
Q4 2021

Feb 14, 2022

SELL
$54.9 - $105.21 $1.65 Million - $3.16 Million
-30,000 Reduced 5.65%
500,715 $31.5 Million
Q3 2021

Nov 15, 2021

BUY
$105.0 - $178.37 $17.5 Million - $29.7 Million
166,250 Added 45.61%
530,715 $55.9 Million
Q2 2021

Aug 16, 2021

SELL
$125.11 - $180.0 $2.7 Million - $3.88 Million
-21,557 Reduced 5.58%
364,465 $64.5 Million
Q1 2021

May 14, 2021

BUY
$126.27 - $191.71 $2.72 Million - $4.13 Million
21,557 Added 5.91%
386,022 $51.5 Million
Q4 2020

Feb 12, 2021

BUY
$81.94 - $135.34 $3.04 Million - $5.03 Million
37,145 Added 11.35%
364,465 $49.3 Million
Q2 2019

Aug 14, 2019

BUY
$25.73 - $35.79 $7.91 Million - $11 Million
307,320 Added 1536.6%
327,320 $11.4 Million
Q1 2019

May 15, 2019

SELL
$21.71 - $31.54 $4.64 Million - $6.74 Million
-213,575 Reduced 91.44%
20,000 $590,000
Q4 2018

Feb 13, 2019

BUY
$14.95 - $24.72 $403,664 - $667,464
27,001 Added 13.07%
233,575 $5.42 Million
Q3 2018

Nov 14, 2018

BUY
$17.8 - $25.35 $391,600 - $557,700
22,000 Added 11.92%
206,574 $4.02 Million
Q2 2018

Aug 13, 2018

BUY
$18.0 - $25.01 $180,000 - $250,100
10,000 Added 5.73%
184,574 $4.29 Million
Q1 2018

May 14, 2018

BUY
$20.05 - $26.96 $200,500 - $269,600
10,000 Added 6.08%
174,574 $3.73 Million
Q4 2017

Feb 12, 2018

BUY
$21.23 - $34.09 $1.46 Million - $2.34 Million
68,729 Added 71.71%
164,574 $3.49 Million
Q3 2017

Nov 13, 2017

BUY
$27.0 - $31.11 $2.59 Million - $2.98 Million
95,845
95,845 $2.59 Million

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.31B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.